Somatic	B:C0037645
Therapy	I:C0037645
of	O
a	O
Mouse	B:C0025929
SMA	B:C0026847
Model	B:C0012644
with	O
a	O
U7	B:C2678677
snRNA	I:C2678677
Gene	I:C2678677
Correcting	O
SMN2	B:C1420258
Splicing	B:C0035687
.	O

Spinal	B:C0026847
Muscular	I:C0026847
Atrophy	I:C0026847
is	O
due	O
to	O
the	O
loss	O
of	O
SMN1	B:C1420257
gene	B:C0314627
function	I:C0314627
.	O

The	O
duplicate	B:C0600497
gene	I:C0600497
SMN2	B:C1420258
produces	O
some	O
,	O
but	O
not	O
enough	O
,	O
SMN	B:C4283935
protein	I:C4283935
because	O
most	O
transcripts	B:C1519595
lack	O
exon	B:C0015295
7	I:C0015295
.	O

Thus	O
,	O
promoting	O
the	O
inclusion	O
of	O
this	O
exon	B:C0015295
is	O
a	O
therapeutic	O
option	O
.	O

We	O
show	O
that	O
a	O
somatic	B:C0037645
gene	I:C0037645
therapy	I:C0037645
using	O
the	O
gene	B:C0017337
for	O
a	O
modified	B:C2678677
U7	I:C2678677
RNA	I:C2678677
which	O
stimulates	O
this	O
splicing	B:C0035687
has	O
a	O
profound	O
and	O
persistent	O
therapeutic	B:C1527144
effect	I:C1527144
on	O
the	O
phenotype	O
of	O
a	O
severe	O
Spinal	B:C0026847
Muscular	I:C0026847
Atrophy	I:C0026847
mouse	B:C2986594
model	I:C2986594
.	O

To	O
this	O
end	O
,	O
the	O
U7	B:C2678677
gene	I:C2678677
and	O
vector	B:C0017397
and	O
the	O
production	O
of	O
pure	O
,	O
highly	O
concentrated	O
self	B:C0001483
-	I:C0001483
complementary	I:C0001483
(	I:C0001483
sc	I:C0001483
)	I:C0001483
adenovirus	I:C0001483
-	O
associated	O
virus	B:C0001483
9	I:C0001483
vector	B:C1520007
particles	I:C1520007
were	O
optimized	O
.	O

Introduction	O
of	O
the	O
functional	O
vector	B:C0017397
into	O
motoneurons	B:C0026609
of	O
newborn	O
Spinal	B:C0026847
Muscular	I:C0026847
Atrophy	I:C0026847
mice	B:C0025929
by	O
intracerebroventricular	B:C0595818
injection	B:C1533685
led	O
to	O
a	O
highly	O
significant	O
,	O
dose	O
-	O
dependent	O
increase	O
in	O
life	O
span	O
and	O
improvement	O
of	O
muscle	B:C0231484
functions	I:C0231484
.	O

Besides	O
the	O
central	B:C3714787
nervous	I:C3714787
system	I:C3714787
,	O
the	O
therapeutic	O
U7	B:C2678677
RNA	I:C2678677
was	O
expressed	B:C0017262
in	O
the	O
heart	B:C0018787
and	O
liver	B:C0023884
which	O
may	O
additionally	O
have	O
contributed	O
to	O
the	O
observed	O
therapeutic	O
efficacy	O
.	O

This	O
approach	B:C0449445
provides	O
an	O
additional	O
therapeutic	O
option	O
for	O
Spinal	B:C0026847
Muscular	I:C0026847
Atrophy	I:C0026847
and	O
could	O
also	O
be	O
adapted	O
to	O
treat	B:C0087111
other	O
diseases	B:C0012634
of	O
the	O
central	B:C3714787
nervous	I:C3714787
system	I:C3714787
with	O
regulatory	B:C0017337
small	I:C0017337
RNA	I:C0017337
genes	I:C0017337
.	O

